Products for Research Use Only
RegisterLogin

LY2510924

CAT: 0804-HY-12488-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12488-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.
CAS Number
1088715-84-7
UNSPSC
12352209
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/LY2510924.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
O=C(NCC(N[C@H](CCC(N[C@H]1CC2=CC=CC=C2)=O)C(N[C@H](C(N)=O)CCCCNC(C)C)=O)=O)[C@@H](NC([C@@](NC([C@@H](NC([C@H](NC1=O)CC3=CC=C(O)C=C3)=O)CCCCNC(C)C)=O)([H])CCCNC(N)=N)=O)CC4=CC(C=CC=C5)=C5C=C4
Molecular Formula
C62H88N14O10
Molecular Weight
1189.45
References & Citations
[1]Peng SB, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015 Feb;14 (2) :480-90.|[2]Cho BS, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 9;126 (2) :222-32.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR4

Alternative Products

CatalogName
BA5294-25LY2510924
A22025-25LY2510924 25mg
A22025-100LY2510924 100mg
A22025-50LY2510924 50mg
A22025-1LY2510924 1mg
A22025-10LY2510924 10mg
A22025-5LY2510924 5mg
T15805L-01LY2510924 acetate (1088715-84-7 free base)

Popular Products